E. Griggs

发表

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Testing for SARS-CoV-2 among cruise ship travelers repatriated to the United States, February to March 2020

J. D. da Silva, J. Gold, M. Honein, 2021, medRxiv.

Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021.

William F. Fadel, S. E. Reese, C. Mcevoy, 2021, MMWR. Morbidity and mortality weekly report.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2022, medRxiv.

Factors Associated with Positive SARS-CoV-2 Test Results in Outpatient Health Facilities and Emergency Departments Among Children and Adolescents Aged <18 Years — Mississippi, September–November 2020

Manish M Patel, B. Flannery, C. Arriola, 2020, MMWR. Morbidity and mortality weekly report.

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2022, MMWR. Morbidity and mortality weekly report.

Role of Age in the Spread of Influenza, 2011–2019: Data From the US Influenza Vaccine Effectiveness Network

A. Monto, B. Flannery, E. Belongia, 2022 .

Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network — United States, March–June 2020

Jay S. Steingrub, Todd W. Rice, Manish M. Patel, 2020, MMWR. Morbidity and mortality weekly report.

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years — VISION Network, 10 States, April 2021–January 2022

William F. Fadel, S. E. Reese, M. Stockwell, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022

William F. Fadel, C. Mcevoy, M. Stockwell, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings

S. Schrag, K. Natarajan, S. Grannis, 2021, The New England journal of medicine.

Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021

William F. Fadel, Sarah E. Reese, C. Mcevoy, 2021, MMWR. Morbidity and mortality weekly report.

Characteristics of Adult Outpatients and Inpatients with COVID-19 — 11 Academic Medical Centers, United States, March–May 2020

Manish M Patel, M. Exline, Akram Khan, 2020, MMWR. Morbidity and mortality weekly report.

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, BMJ.

Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19–associated hospitalizations among immunocompromised adults—Nine States, January–September 2021

S. E. Reese, C. Mcevoy, S. Schrag, 2021, American Journal of Transplantation.

Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.

S. E. Reese, C. Mcevoy, P. Embí, 2022, The Journal of infectious diseases.

Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods

William F. Fadel, S. E. Reese, C. Mcevoy, 2023, JAMA network open.

Role of Age in Spread of Influenza, 2011-2019, U.S. Influenza Vaccine Effectiveness Network.

Manish M Patel, A. Monto, B. Flannery, 2021, American journal of epidemiology.

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022

S. E. Reese, C. Mcevoy, R. Link-Gelles, 2023, MMWR. Morbidity and mortality weekly report.

Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents.

S. E. Reese, M. Stockwell, R. Link-Gelles, 2023, Pediatrics.

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021–February 2022, VISION Network: a retrospective cohort study

R. Link-Gelles, P. Embí, K. Natarajan, 2023, Lancet regional health. Americas.